Article info
PDFExtended reports
Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab
- Correspondence to:
Antti Kuuliala
Haartman Institute, Department of Bacteriology and Immunology, PO Box 21 (Haartmaninkatu 3), FIN-00014 Helsingin Yliopisto, Helsinki, Finland; antti.kuuliala{at}helsinki.fi
Citation
Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab
Publication history
- Accepted June 2, 2005
- First published June 7, 2005.
Online issue publication
January 09, 2022
Article Versions
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Annals of the Rheumatic Diseases